

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

Tadalafil is an established prescription phosphodiesterase type 5 (PDE5) inhibitor that sustains nitric-oxide and cyclic-guanosine-monophosphate signaling and can improve endothelial function. Improved cerebral perfusion at 5 mg daily is plausible. Beyond its approved uses for erectile dysfunction and benign prostatic hyperplasia, its effects on vascular and cellular-protection pathways make an experimental healthspan benefit plausible. [13,14,17,18]

💉💉💉 Tadalafil has an established safety profile for long-term use within approved prescribing parameters, with appropriate attention to cardiovascular status, kidney and liver function, contraindications, and interacting medications. [12,14]

★ Plausibly effective for improving healthspan. [3,17,22,24]

Disclaimer: These notes are not authoritative and should not be interpreted as definitive scientific guidance. They are summaries, compilations and plausible extrapolations drawn from the most relevant research I was able to locate, and may omit nuances, conflicting data, or emerging evidence. The material reflects an attempt to organize and understand complex topics, not to provide clinical recommendations or expert interpretation.

This document was updated 13-Oct-26. The most recent version of this document is available at
<https://pdfs.researcher6076.com/pdfs/tadalafil.pdf>



Tadalafil has long, well-documented clinical use and safety surveillance within its approved indications. Appropriate use depends on individual renal function, cardiovascular status, interacting medications, and labeled contraindications. [12,14]

Current mechanistic, preclinical, biomarker, and observational evidence supports a plausible tadalafil healthspan benefit. Randomized trials using aging-relevant clinical outcomes would be needed to support a higher evidence classification. [3,17,21,22,24]

- **Preclinical neurovascular and cognitive studies:** Multiple rodent studies report that tadalafil crosses the blood–brain barrier and reverses cognitive deficits in Alzheimer’s models, improves hippocampal signaling (pCREB/BDNF), and reduces oxidative stress and tau pathology in some experiments, providing mechanistic plausibility for neuroprotective effects. [2,7,26]
- **Endothelial function RCTs and biomarker trials:** Short randomized trials and controlled studies testing daily low-dose tadalafil, for example 5 mg, report

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

improvements in flow-mediated dilation and endothelial biomarkers in some cohorts, though results are inconsistent and effect sizes are modest in several trials. [13,18,19]

- **Tadalafil cardiovascular and mortality data; PDE5-inhibitor dementia data.** One large propensity-matched retrospective cohort associated tadalafil use with lower rates of major adverse cardiovascular events and all-cause mortality in men with erectile dysfunction, supporting possible cardiovascular and mortality benefits. For dementia, observational findings across the PDE5-inhibitor class are mixed: large database analyses of sildenafil reported lower incidence, while tadalafil-specific and mixed-PDE5 studies reported neutral associations. Dementia prevention remains speculative. [3–6,20,22]

Dosing

A plausible dose for healthspan is

- **Tadalafil: 5 mg daily.**

This approved long-term dose treats benign prostatic hyperplasia and produces relevant vascular and endothelial effects. [12–14]

Benefits (Beyond Prostate and ED)

- **Endothelial signaling:** Tadalafil inhibits phosphodiesterase type 5, sustaining cyclic guanosine monophosphate and nitric-oxide signaling and producing vasodilation. Daily tadalafil can improve endothelial function in some human populations. These effects could plausibly protect vascular-dependent tissues from aspects of age-related decline. [13,14,18,19]
- **Microvascular perfusion:** Tadalafil is likely to improve perfusion and oxygen delivery in tissues responsive to nitric-oxide and cyclic-guanosine-monophosphate signaling. Animal and limited human evidence make support for cardiac, renal, and skeletal-muscle perfusion likely. Improved cerebral perfusion at 5 mg daily, preservation of multi-organ function, and slower age-related decline remain plausible. [10,17,24,25,27]
- **Cerebral and cognitive support:** In patients with cerebral small-vessel disease and prior stroke or transient ischemic attack, tadalafil at 20 mg daily for three months increased whole-brain cerebral blood flow compared with placebo. Improved cerebral perfusion at 5 mg daily is plausible. Cognitive and neuroprotective benefits are plausible based primarily on animal models. [2,9,17,21,26]
- **Vascular inflammation and platelet signaling:** Human studies support favorable effects on endothelial and inflammatory biomarkers, while limited evidence suggests

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

reduced platelet activation in some populations. Observational outcome studies make a reduction in atherothrombotic events possible. [3,11,13,22]

- **Cardiovascular outcomes:** Tadalafil use is associated with fewer major cardiovascular events and lower all-cause mortality in men with erectile dysfunction. A causal cardiovascular and mortality benefit is possible. [3,22]
- **Lipid-related biomarkers:** In a 12-week randomized trial in sexually active men with benign prostatic hyperplasia and erectile dysfunction, tadalafil at 2.5 or 5 mg daily improved lipid-related biomarkers, including the atherogenic index of plasma, with greater improvement at 5 mg. A resulting reduction in cardiovascular events is possible. [13]
- **Lymphatic signaling:** Tadalafil could plausibly modulate lymphatic smooth-muscle tone through cGMP signaling. Effects on lymphatic drainage are likely to depend on the tissue and condition, because relaxation can reduce resistance to flow while also suppressing active lymphatic pumping. [15,16]
- **Mitochondrial protection and autophagy:** Tadalafil likely supports mitochondrial respiration, reduces excessive reactive-oxygen-species production, and modulates autophagy in responsive tissues, based on animal studies. Broader cellular protection in humans is plausible. [24,26]

How These Map to Healthspan

Vascular health is a major determinant of multi-organ aging; preserving endothelial function and microcirculation reduces the burden of ischemia, inflammation, and organ dysfunction that drive morbidity and mortality. Sustained NO–cGMP signaling therefore targets a root contributor to age-related functional decline rather than a single disease. [3,17,22,24]

Cautions

- **Nitrates or guanylate-cyclase stimulators:** Tadalafil is contraindicated with nitrates in any form and with guanylate-cyclase stimulators such as riociguat because of the risk of clinically significant hypotension. [14]
- **Cardiovascular or blood-pressure concerns:** Unstable cardiovascular disease, significant hypotension, concurrent alpha-blockers, antihypertensive therapy, or substantial alcohol intake warrant individualized assessment because tadalafil can add to blood-pressure reduction. [14]

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

- **Strong CYP3A4 inhibitors:** Medications such as ketoconazole and ritonavir increase tadalafil exposure. When used with a strong CYP3A4 inhibitor, once-daily tadalafil should not exceed 2.5 mg daily. [14]
- **Pregnancy and breastfeeding:** Tadalafil use specifically for healthspan during pregnancy or breastfeeding is unestablished. Use should be limited to clinician-directed treatment for an established medical indication. [14]
- **Renal impairment:** Once-daily tadalafil is not recommended when creatinine clearance is below 30 mL/min or during hemodialysis. Moderate renal impairment may require a lower starting dose, depending on the treatment indication. [14]
- **Hepatic impairment:** Once-daily tadalafil requires caution in mild-to-moderate hepatic impairment and is not recommended in severe hepatic impairment. [14]
- **Known serious hypersensitivity to tadalafil.** [14]

Side effects

- Common: headache, dyspepsia, back pain, myalgia, nasal congestion, and flushing. [14]
- Uncommon but important reported effects: Clinically significant hypotension, prolonged erection, sudden visual loss, and sudden hearing loss. An erection lasting more than four hours requires emergency care. Stop tadalafil and seek prompt medical attention for sudden vision or hearing loss. [14]

Biological Mechanisms

Primary vascular / signaling effects

Tadalafil inhibits phosphodiesterase type 5, sustaining cyclic guanosine monophosphate and nitric-oxide signaling and producing vasodilation. [13,14,18,19] Tadalafil is likely to improve perfusion and oxygen delivery in tissues responsive to nitric-oxide and cyclic-guanosine-monophosphate signaling. Animal and limited human evidence make support for cardiac, renal, and skeletal-muscle perfusion likely. [10,17,24,25,27] Tadalafil is likely to improve blood flow and effects on cyclic-guanosine-monophosphate, CREB, and BDNF signaling, support for metabolite clearance, synaptic function, and protection from neurodegenerative processes. [2,17,26]

Downstream maintenance and protective programs

Tadalafil likely supports mitochondrial respiration, reduces excessive reactive-oxygen-species production, and modulates autophagy in responsive tissues, based on animal studies. [24,26] Human studies support favorable effects on endothelial and inflammatory biomarkers, while limited evidence suggests reduced platelet activation in some

This document provides educational summaries of limited and evolving peptide data. Nothing here is medical advice for diagnosis or treatment. © 2026

Researcher6076

*Updated:
13-Oct-26*

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

populations. [3,11,13,22] Tadalafil's cGMP signaling plausibly modulates lymphatic smooth-muscle tone. [15,16]

Sex-Specific Differences in PDE5 Inhibitor Data

Most large observational datasets evaluating PDE5 inhibitors involve men because these drugs are primarily prescribed for male urologic indications. Tadalafil is likely to produce relevant vascular and microcirculatory effects in women because the underlying NO–cGMP–PDE5 pathway operates in both sexes and human studies demonstrate physiological responses in women. Broader cardiovascular and healthspan benefits in women are possible, while the magnitude of those benefits may vary with hormonal status, vascular biology, and disease context. [10,22,25]

Conclusions

Tadalafil is an established prescription PDE5 inhibitor with a long clinical safety history. Its effects on endothelial function, tissue perfusion, and related protective pathways provide a biologically coherent rationale for a plausible healthspan benefit. Preclinical, human biomarker, and observational findings support this experimental application. [3,12,14,17,22,24]

References

1. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid- β load in an Alzheimer's disease mouse model. *J Neurosci*. 2009;29(25):8075–8086. doi:10.1523/JNEUROSCI.0864-09.2009.
2. García-Barroso C, Ricobaraza A, Pascual-Lucas M, et al. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. *Neuropharmacology*. 2013;64:114–123. doi:10.1016/j.neuropharm.2012.06.052.
3. Kloner RA, Stanek E, Desai K, et al. The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction. *Clin Cardiol*. 2024;47(2):e24234. doi:10.1002/clc.24234.
4. Gronich N, Stein N, Saliba W. Phosphodiesterase-5 inhibitors and dementia risk: a real-world study. *Neuroepidemiology*. 2025;59(3):193–202. doi:10.1159/000540057.
5. Desai RJ, Mahesri M, Lee SB, et al. No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines study. *Brain Commun*. 2022;4(5):fcac247. doi:10.1093/braincomms/fcac247.

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

6. Abouelmagd ME, Abdelmeseh M, Elrosasy A, et al. Phosphodiesterase-5 inhibitors use and the risk of Alzheimer's disease: a systematic review and meta-analysis. *Neurol Sci.* 2024;45(11):5261–5270. doi:10.1007/s10072-024-07583-9.
7. El-Bakly W, Wagdy O, Sobhy A, et al. The efficacy and underlying mechanism of phosphodiesterase-5 inhibitors in preventing cognitive impairment and Alzheimer pathology: a systematic review of animal studies. *Behav Brain Res.* 2019;372:112004. doi:10.1016/j.bbr.2019.112004.
8. Ölmestig J, Marlet IR, Hansen RH, et al. Tadalafil may improve cerebral perfusion in small-vessel occlusion stroke: a pilot study. *Brain Commun.* 2020;2(1):fcaa020. doi:10.1093/braincomms/fcaa020.
9. Ölmestig J, Mortensen KN, Thomas MB, et al. Tadalafil treatment in patients with cerebral small vessel disease: the ETLAS-2 randomized clinical trial. *Stroke.* 2025;56(10):2846–2857. doi:10.1161/STROKEAHA.125.051602.
10. Murdolo G, Sjöstrand M, Strindberg L, Lönnroth P, Jansson PA. The selective phosphodiesterase-5 inhibitor tadalafil induces microvascular and metabolic effects in type 2 diabetic postmenopausal females. *J Clin Endocrinol Metab.* 2013;98(1):245–254. doi:10.1210/jc.2012-1830.
11. De Bon E, Bonanni G, Saggiorato G, Bassi PF, Cella G. Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study. *Angiology.* 2010;61(6):602–606. doi:10.1177/0003319710362977.
12. Porst H, Rajfer J, Casabé A, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. *J Sex Med.* 2008;5(9):2160–2169. doi:10.1111/j.1743-6109.2008.00935.x.
13. Abomandour A, El-Shoura EAM, Fathi BA, et al. Effects of tadalafil on endothelial, angiogenic, metabolic, and microRNA biomarker profiles in sexually active men with BPH and erectile dysfunction: a randomized controlled trial. *Naunyn Schmiedeberg's Arch Pharmacol.* Published online August 1, 2026. doi:10.1007/s00210-026-05771-2.
14. U.S. National Library of Medicine. Tadalafil tablets: prescribing information. *DailyMed.* <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09ad27a1-3908-4533-b84c-7a7fd3514101>. Accessed October 6, 2026.
15. Gasheva OY, Gashev AA, Zawieja DC. Cyclic guanosine monophosphate and the dependent protein kinase regulate lymphatic contractility in rat thoracic duct. *J Physiol.* 2013;591(18):4549–4565. doi:10.1113/jphysiol.2013.258681.
16. Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. *N Engl J Med.* 2012;366(4):384–386. doi:10.1056/NEJMc1112482.

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

17. Ölmestig J, Mortensen KN, Fagerlund B, et al. Neurovascular effects of tadalafil in patients with cerebral small vessel disease: ETLAS-2 substudy. *Brain Commun.* 2026;8(4):fcag309. doi:10.1093/braincomms/fcag309.
18. Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. *Eur Urol.* 2005;47(2):214–220; discussion 220–222. doi:10.1016/j.eururo.2004.10.002.
19. Amano T, Earle C, Imao T, Matsumoto Y, Kishikage T. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. *Aging Male.* 2018;21(1):77–82. doi:10.1080/13685538.2017.1367922.
20. Fang J, Zhang P, Zhou Y, et al. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease. *Nat Aging.* 2021;1(12):1175–1188. doi:10.1038/s43587-021-00138-z. Author correction: *Nat Aging.* 2023;3:908. doi:10.1038/s43587-023-00396-z.
21. Ölmestig J, Mortensen KN, Thomas MB, et al. Cognitive outcomes after tadalafil treatment in patients with cerebral small vessel disease: ETLAS-2 sub-study. *Cereb Circ Cogn Behav.* 2025;9:100520. doi:10.1016/j.cccb.2025.100520.
22. Soulaïdopoulos S, Terentes-Printzios D, Ioakeimidis N, Tsioufis KP, Vlachopoulos C. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother.* 2024;10(5):403–412. doi:10.1093/ehjcvp/pvae029.
23. Pauls MMH, Binnie LR, Benjamin P, et al. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. *Alzheimers Dement.* 2022;18(12):2393–2402. doi:10.1002/alz.12559.
24. Koka S, Aluri HS, Xi L, Lesnefsky EJ, Kukreja RC. Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1 α signaling. *Am J Physiol Heart Circ Physiol.* 2014;306(11):H1558–H1568. doi:10.1152/ajpheart.00865.2013.
25. Fryk E, Silva VRR, Bauzá-Thorbrügge M, et al. Feasibility of high-dose tadalafil and effects on insulin resistance in well-controlled patients with type 2 diabetes (MAKROTAD): a single-centre, double-blind, randomised, placebo-controlled, cross-over phase 2 trial. *EClinicalMedicine.* 2023;59:101985. doi:10.1016/j.eclinm.2023.101985.
26. Salem MA, Budzyńska B, Kowalczyk J, El Sayed NS, Mansour SM. Tadalafil and bergapten mitigate streptozotocin-induced sporadic Alzheimer's disease in mice via

Tadalafil (Rx Off label)

(Tadalafil 5 mg, daily)

modulating neuroinflammation, PI3K/Akt, Wnt/ β -catenin, AMPK/mTOR signaling pathways. Toxicol Appl Pharmacol. 2021;429:115697. doi:10.1016/j.taap.2021.115697.

27. Nakashima MA, Delfrate G, Albino LB, et al. Impact of tadalafil on cardiovascular and organ dysfunction induced by experimental sepsis. *Acute Crit Care*. 2025;40(1):46–58. doi:10.4266/acc.002904.